Q linea AB (QLINEA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Q linea AB (QLINEA) has a cash flow conversion efficiency ratio of -0.118x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-39.80 Million ≈ $-4.28 Million USD) by net assets (Skr338.00 Million ≈ $36.37 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Q linea AB - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Q linea AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Q linea AB balance sheet liabilities for a breakdown of total debt and financial obligations.
Q linea AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Q linea AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Solidion Technology Inc.
NASDAQ:STI
|
0.020x |
|
Sangshin Electronics Co. Ltd
KQ:263810
|
0.031x |
|
Crypto Blockchain Industries SA
PA:ALCBI
|
-0.141x |
|
CrystalGenomics Inc
KQ:083790
|
-0.129x |
|
QTC Energy Public Company Limited
BK:QTC
|
0.104x |
|
EON Resources Inc.
NYSE MKT:EONR
|
-0.127x |
|
Shanghai Material Trading Co Ltd B
SHG:900927
|
-0.215x |
|
North Energy ASA
OL:NORTH
|
-0.013x |
Annual Cash Flow Conversion Efficiency for Q linea AB (2016–2025)
The table below shows the annual cash flow conversion efficiency of Q linea AB from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Q linea AB.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr338.00 Million ≈ $36.37 Million |
Skr-162.12 Million ≈ $-17.45 Million |
-0.480x | -107.22% |
| 2024-12-31 | Skr-27.46 Million ≈ $-2.95 Million |
Skr-182.50 Million ≈ $-19.64 Million |
6.647x | +651.58% |
| 2023-12-31 | Skr189.64 Million ≈ $20.41 Million |
Skr-228.52 Million ≈ $-24.59 Million |
-1.205x | +22.36% |
| 2022-12-31 | Skr161.63 Million ≈ $17.39 Million |
Skr-250.86 Million ≈ $-27.00 Million |
-1.552x | -162.15% |
| 2021-12-31 | Skr430.79 Million ≈ $46.36 Million |
Skr-255.05 Million ≈ $-27.45 Million |
-0.592x | +5.14% |
| 2020-12-31 | Skr380.20 Million ≈ $40.92 Million |
Skr-237.31 Million ≈ $-25.54 Million |
-0.624x | -25.36% |
| 2019-12-31 | Skr340.94 Million ≈ $36.69 Million |
Skr-169.76 Million ≈ $-18.27 Million |
-0.498x | -108.34% |
| 2018-12-31 | Skr513.46 Million ≈ $55.26 Million |
Skr-122.71 Million ≈ $-13.21 Million |
-0.239x | +99.43% |
| 2017-12-31 | Skr1.51 Million ≈ $162.72K |
Skr-62.87 Million ≈ $-6.77 Million |
-41.577x | -565.28% |
| 2016-12-31 | Skr8.45 Million ≈ $909.79K |
Skr-52.83 Million ≈ $-5.69 Million |
-6.250x | -- |
About Q linea AB
Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, European Union, the Middle East, and the United States. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, includin… Read more